EVAR - Lombard Medical, Inc.

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
0.223
-0.042 (-15.881%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.265
Open0.265
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.220 - 0.266
52 Week Range0.220 - 0.920
Volume180,987
Avg. Volume84,082
Market Cap6.23M
Beta1.46
PE Ratio (TTM)N/A
EPS (TTM)-1.539
Earnings DateJun 16, 2017 - Jun 17, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Trade prices are not sourced from all markets
  • OTC Markets Group Welcomes Lombard Medical to OTCQX
    PR Newswire12 days ago

    OTC Markets Group Welcomes Lombard Medical to OTCQX

    NEW YORK , Nov. 9, 2017 /PRNewswire/ --  OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Lombard Medical, Inc.  (OTCQX: EVARF) ...

  • What You Must Know About Lombard Medical Inc’s (EVAR) Risks
    Simply Wall St.2 months ago

    What You Must Know About Lombard Medical Inc’s (EVAR) Risks

    For Lombard Medical Inc’s (NASDAQ:EVAR) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. EVAR is exposedRead More...

  • Business Wire2 months ago

    Lombard Medical’s New Delivery System for Aorfix™ Endovascular Aortic Aneurysm Repair System Launched in Japan

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular abdominal aortic aneurysm endovascular repair products, today announced the full commercial launch in Japan of its new low-profile IntelliFlex™ LP delivery system for the Aorfix™ AAA system.

  • One Thing To Consider Before Buying Lombard Medical Inc (EVAR)
    Simply Wall St.2 months ago

    One Thing To Consider Before Buying Lombard Medical Inc (EVAR)

    If you are a shareholder in Lombard Medical Inc’s (NASDAQ:EVAR), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...

  • Business Wire2 months ago

    Lombard Medical Appoints Jonathan Hornsby as Vice President, Sales & Marketing

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced the appointment of Jonathan Hornsby as Vice President, Sales & Marketing, effective immediately.

  • Business Wire2 months ago

    Lombard Medical Announces Completion of Restructuring and Implementation of Strategic Plan to Achieve Profitability

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced completion of a restructuring following the implementation of its new strategy to focus sales efforts in the UK, Japan and China, and reduce operating and manufacturing costs in order to achieve cash flow breakeven in the near term.

  • Lombard Medical, Inc. :EVAR-US: Earnings Analysis: Q4, 2016 By the Numbers : May 26, 2017
    Capital Cube6 months ago

    Lombard Medical, Inc. :EVAR-US: Earnings Analysis: Q4, 2016 By the Numbers : May 26, 2017

    Categories: Yahoo FinanceGet free summary analysis Lombard Medical, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Lombard Medical, Inc. – Endologix, Inc., LeMaitre Vascular, Inc., Cardiovascular Systems, Inc. and Boston Scientific Corporation (ELGX-US, LMAT-US, CSII-US and BSX-US) that have also reported for this period. ... Read more (Read more...)

  • Business Wire6 months ago

    Lombard Medical Announces First Patient Enrolled and Treated in the ALTITUDE Registry for the Altura® Stent Graft System

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System.

  • Business Wire7 months ago

    Lombard Medical’s Endovascular Product Portfolio Presented at Scientific Sessions of the 39th Annual Charing Cross International Symposium

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that its portfolio of endovascular stent graft systems, Altura® and Aorfix™, were featured in scientific presentations at the 39th annual Charing Cross International Symposium in London on April 25 - 26.

  • Business Wire7 months ago

    Lombard Medical Appoints New CEO

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that Kurt Lemvigh has been appointed as its new Chief Executive Officer, effective immediately.

  • Associated Press7 months ago

    Lombard Medical reports 4Q loss

    The Irvine, California-based company said it had a loss of 37 cents per share. Losses, adjusted for asset impairment costs and non-recurring costs, came to 25 cents per share. The medical device company ...

  • Business Wire7 months ago

    Lombard Medical Reports 2016 Fourth Quarter, Full Year Financial Results

    Lombard Medical, Inc. , a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms, today reported financial results for the fourth quarter and year ended December 31, 2016.

  • Business Wire7 months ago

    Lombard Medical’s CEO Steps Down

    Lombard Medical, Inc. , a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that Simon Hubbert has stepped down from his position as CEO on April 18 after serving in the role for more than six years.

  • Business Wire8 months ago

    Lombard Medical and MicroPort Scientific Corporation Finalize Strategic Partnership Agreements

    Lombard Medical, Inc. , a medical device company focused on endovascular aneurysm repair, and MicroPort Scientific Corporation , a leading global manufacturer and marketer of a diversified portfolio of medical devices, today announced the parties have finalized the definitive agreements to their strategic partnership first announced on December 19, 2016.

  • Business Wire9 months ago

    Lombard Medical Announces Successful Completion of First 15 Cases in Japan for IntelliFlex™ LP Delivery System for the Aorfix™ Endovascular Stent Graft

    Lombard Medical, Inc. , a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms , today announced that physicians in Japan have successfully treated the first 15 patients using its innovative new IntelliFlex™ LP Delivery System for the Aorfix™ Endovascular Stent Graft since launch on February 1, 2017.

  • Business Wire11 months ago

    Lombard Medical Announces Regulatory Approval in Japan for IntelliFlex™ LP Delivery System for the Aorfix™ Abdominal Aortic Aneurysm Endovascular Stent Graft

    Lombard Medical, Inc. , a medical device company focused on endovascular aneurysm repair of abdominal aortic aneurysms , today announced approval from the Japanese Ministry of Health, Labour and Welfare for its IntelliFlex™ Low Profile Delivery System for the Aorfix™ Endovascular Stent Graft.

  • Zacks Small Cap Research11 months ago

    EVAR: $15M Investment, Additional Positive Outcomes Data

    Lombard (EVAR) announced that they entered into an agreement with MicroPort Scientific Corporation, a Shanghai, China-based medical device company, whereby MicroPort invested a total of $15M in EVAR through a combination of common equity and convertible debt.  Two MicroPort representatives will join EVAR’s board of directors.  The deal brings EVAR not only financing on what we think are very reasonable terms, but also what could be relatively seamless commercial entry of Aorfix and Altura into the large Chinese and Brazilian markets. 5 years but which can be extended).  Interest on the notes is payment-in-kind (PIK) and calculated as six-month LIBOR (currently 1.30%) plus 4%.  The PIK interest, which is capitalized and added to the principal, reduces cash outflows. Following the financing, MicroPort owns approximately 29% of EVAR’s outstanding shares.  The agreement stipulates that MicroPort cannot own more than 49% of the voting power of EVAR.  As such, in the event a conversion would result in MicroPort owning more than 49%, EVAR will pay in cash an amount equal to the number of shares that MicroPort is entitled to above a 49% interest.

  • Business Wire11 months ago

    Lombard Medical and MicroPort Scientific Corporation Announce Strategic Partnership and Investment Agreement

    Lombard Medical, Inc. , a medical device company focused on endovascular aneurysm repair, and MicroPort Scientific Corporation , a leading global manufacturer and marketer of a diversified portfolio of medical devices, today announced a strategic partnership and a significant infusion of capital into Lombard Medical by MicroPort.